Capecitabine, DNA/RNA Synthesis Inhibitor
Por um escritor misterioso
Descrição
Capecitabine is an oral proagent that is converted to its active metabolite, 5-FU, by thymidine phosphorylase. - Mechanism of Action & Protocol.
is a tumor-selective fluoropyrimidine carbamate, which achieves higher intratumoral 5-FU level with lower toxicity than 5-FU.
Capecitabine
Frontiers 5-Fluorouracil: A Narrative Review on the Role of Regulatory Mechanisms in Driving Resistance to This Chemotherapeutic Agent
Effects of microbiota on anticancer drugs: Current knowledge and potential applications - eBioMedicine
5‑Fluorouracil and capecitabine therapies for the treatment of colorectal cancer (Review)
THOC5 complexes with DDX5, DDX17, and CDK12 to regulate R loop structures and transcription elongation rate
5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition - ScienceDirect
Frontiers PARP inhibitors combined with radiotherapy: are we ready?
Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside
POR Clinical benefits of oral capecitabine over intravenous 5-fluorouracyl regimen in case of neoadjuvant chemoradiotherapy followed by surgery for locally advanced rectal cancer
de
por adulto (o preço varia de acordo com o tamanho do grupo)
